WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

Summary

The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.

Conditions

• Lymphoma
• Sarcoma

Interventions

PROCEDURE

Electrocardiogram

All participants receive a standard 12-lead ECG when they present for follow-up 1 year after completion of anthracycline-based therapy. All participants will also record a 6-lead Kardia (AliveCor, Mountain View, CA, USA) and 1-lead Apple Watch (Apple, Cupertino, CA, USA) ECG with Mayo-owned or participant-owned devices. Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs.

PROCEDURE

Echocardiogram

All participants will have an echocardiogram as part of standard of care when they present for their follow-up 1 year after completion of anthracycline-based therapy.

PROCEDURE

LVEF echocardiogram

Participants will undergo a limited LVEF echocardiogram at the 6-month post therapy visit.

OTHER

Apple Watch

Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs. Longitudinal participants will be asked to transmit weekly cardio fitness (estimates of peak VO2) from baseline to 1-year post therapy.

PROCEDURE

Biospecimen collection

Undergo blood draw

OTHER

Questionnaires

Participants fill out 2 questionnaires: 1) the Kansas City Cardiomyopathy-12 (KCCQ-12) Questionnaire, and 2) the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ore 30 (EORTC QLQ-C30) to evaluate health related quality of life and heart failure symptoms.

OTHER

Cardio-pulmonary exercise test

Undergo CPET to assess the response of heart and lungs to exercise.

OTHER

6 minute walk test

Complete a 6MWT, to see how far participants can walk on a hard, flat surface for 6 minutes

OTHER

Grip strength test

A hand-held device called a dynamometer will be used to measure the muscle strength in hand/forearm

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Joerg Herrmann, MD · Mayo Clinic

Study Design

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-07-18

Primary Completion

2029-06-29

Completion

2029-06-29

Countries

• United States

Study Locations